Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Dec 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-12-21

Reporting Person: Ross Douglas T. (Former CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-21	Common Stock, no par value	A	213797	—	Acquired	234114	Direct

Footnotes

F1: The restricted stock units will vest as follows: (i) one-third on January 31, 2023, (ii) one-third on February 28, 2023, and (ii) one-third on March 31, 2023 (each such date, a "Vesting Date"), in each case, subject to the Reporting Person's continuous service as a consultant on each applicable Vesting Date.